AHL
DFTX

Abel Hall LLC’s Definium Therapeutics DFTX Stock Holding History

Abel Hall LLC’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
+7,551
New +$187K 0.06% 394

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Abel Hall LLC's DFTX Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 7,551 shares worth $355K. The stake represents 0.06% of the portfolio and ranks #394 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Abel Hall LLC held 7,551 shares of Definium Therapeutics worth $355K as of Q2 2026.
  • Definium Therapeutics was a new Abel Hall LLC position in Q2 2026.
  • Definium Therapeutics made up 0.06% of Abel Hall LLC's portfolio in Q2 2026, its #394 holding.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.